Recently, several novel pharmacologically active compound agonists, PPAR-α ligands, and neurosteroids have been investigated, and some were introduced to the treatment of depression, which should significantly improve the therapeutic strategies of neuropsychiatric disorders. This evidence concerns the gene PPARA and depressive symptom measurement.